P=N/A, N=100, Not yet recruiting, University of Alabama at Birmingham

P2, N=156, Recruiting, Second Affiliated Hospital of Nanchang University | Not yet recruiting --> Recruiting | Trial completion date: May 2028 --> May 2027 | Trial primary completion date: Dec 2027 --> Dec 2026

P=N/A, N=10, Terminated, University of Southern California | N=60 --> 10 | Recruiting --> Terminated; PI left institution. No one resumed the project.

P4, N=0, Withdrawn, University of Southern California | N=30 --> 0 | Trial completion date: Dec 2026 --> Dec 2030 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jul 2026 --> Jul 2029

P3, N=200, Recruiting, The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University

P2, N=36, Terminated, Austin Hospital | Recruiting --> Terminated

P3, N=227, Active, not recruiting, Alliance for Clinical Trials in Oncology | Recruiting --> Active, not recruiting | N=360 --> 227

This review highlights that, despite the absence of pharmacological agents specifically approved for CAC in the United States and Europe, current guidelines recommend multimodal supportive care, including low-dose olanzapine, nutritional support, and exercise-based interventions. Furthermore, we identify recent phase 2 trials targeting the GDF-15 pathway, such as the GDF-15 inhibitor ponsegromab, which have demonstrated significant improvements in body weight and physical activity, suggesting a potential breakthrough in targeted therapies for CAC...It manifests as a lethal systemic pathology that demands early identification and targeted personalized pharmacological and nutritional interventions. Early diagnosis and targeted intervention represent promising strategies for improving survival and quality of life in this high-risk patient population.

P3, N=348, Completed, Murdoch Children's Research Institute (MCRI) | Recruiting --> Completed

P=N/A, N=168, Completed, University of Liverpool | Recruiting --> Completed | N=125 --> 168 | Trial completion date: Jun 2026 --> Nov 2025 | Trial primary completion date: Jun 2026 --> Nov 2025

Through integrated transcriptomic and metabolomic analyses, we demonstrate that BRAFi by vemurafenib (PLX4032) significantly enhances FAO in thyroid cancer cells. The pharmacological inhibition of FAO via thioridazine (Thio) synergizes with BRAFi to suppress tumor growth in vitro, in vivo and in a patient-derived organoid...Consistently, functional studies confirm RUNX1's oncogenic role, as its knockdown reduces cell proliferation, migration, and invasion. In conclusion, our work reveals a metabolic-epigenetic axis underlying adaptive response to BRAFi and identifies RUNX1 as a novel oncogene in thyroid cancer.

P2, N=24, Completed, The University of Technology Sydney | Recruiting --> Completed